Abstract
A Phase 2 Study of ATH434, a Novel Inhibitor of α-synuclein Aggregation, for the Treatment of Multiple System Atrophy (MSA) (P2-3.004)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1212/wnl.0000000000206596
Journal: Neurology | Publication Date: Apr 9, 2024 |
A Phase 2 Study of ATH434, a Novel Inhibitor of α-synuclein Aggregation, for the Treatment of Multiple System Atrophy (MSA) (P2-3.004)
Join us for a 30 min session where you can share your feedback and ask us any queries you have